FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Article

(CCOI, PSEC, PWRM, OPTR, ORFG) Stock Report from PennyOmega.com Dec 29th 2010

Posted, by pennylynnomega on December 29th, 2010

chartstockalert

Alzheimer’s is not an everyday part of growing older, although the most significant known risk factor is increasing age, and the most of people with Alzheimer’s are 65 and older. But Alzheimer’s is not merely a sickness associated with aging. As much as a few per cent of people with the actual illness possess early-onset Alzheimer’s (also referred to as younger-onset), which regularly appears when someone is within his or her 40s or 50s.

Power3 Medical Products, Inc. (OTCBB:PWRM.OB) recently announced that company management believes it is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, to name a few.

In addition, Power3 is a party to several litigation matters, most of which relate to various toxic debt instruments that were entered into by Power3 several years ago when it operated under the tenure of Chairman and CEO, Steven B. Rash.

Power3 Medical is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

More about PWRM at: www.Power3Medical.com

**************************************************************

Cogent Communications Group Inc. (Nasdaq:CCOI) one of the largest Internet service providers in the world, announced that Dave Schaeffer, Cogent’s chief executive officer, will present at the Citi 21st Annual Global Entertainment, Media and Telecommunications Conference at 3:05 p.m. MST, January 4th. The conference is being held at the Arizona Biltmore Resort in Phoenix, AZ.

Cogent Communications is a multinational, Tier 1 facilities-based ISP, consistently ranked as one of the top five networks in the world.

**************************************************************

Prospect Capital Corporation (Nasdaq:PSEC) announced that Prospect has made a second lien secured debt investment of $15 million to support the acquisition of Jordan Healthcare Holdings, Inc. (”Jordan”) by affiliates of Palladium Equity Partners, LLC (”Palladium”). Jordan is the second largest provider of home healthcare services to both Medicare and Medicaid eligible patients in Texas. Based in Mount Vernon, Jordan provides skilled nursing and personal care services to over 13,000 patients in 174 counties throughout Texas.

Prospect Capital Corporation is a closed-end investment company that lends to and invests in private and microcap public businesses.

**************************************************************

Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) announced that it is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, January 12, 2011. Pedro Lichtinger, Optimer’s President and Chief Executive Officer, will present at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time).

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs.

**************************************************************

http://crwewallstreet.com/img/orfg_logo.png

Orofino Gold Corp. (ORFG.PK) (”Orofino Gold” or the “Company”) engages in acquisition, exploration, and development of gold properties in Mexico and Colombia. The company has an option to acquire properties in the Sur de Bolivar Department of Colombia South America. Orofino Gold Corp. was formerly known as SNT Cleaning, Inc. and changed its name to Orofino Gold Corp. in December 2009. The company was founded in 2005 and is based in Central, Hong Kong.

Orofino Gold has several Gold development properties in Colombia, a current hot spot of gold production in the world markets.

The company newly announced that the Board Of Directors have appointed Mr. Ning Shi Long as Chairman of the Board and Executive Director.

Mr. Ary Fernando Pernett Marque has been appointed as the new President/CEO & Executive Director of Orofino Gold Corp. (see full resume on the company website at www.orofinogold.com)

Mr. Pernett will be responsible for all affairs of the Company in Colombia. Mr. Pernett has 30 years of experience working in the Colombian Mining sector and will over the near term choose his new development team to assist in the development of the company’s Senderos de Oro gold camp in the Sur de Bolivar Colombia.

More about ORFG at:www.orofinogold.com

**************************************************************

pobc4

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer:Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer).Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 500,000 shares of 144 stock in Orofino Gold Corp. (PINK SHEETS: ORFG) valued at sixty five thousand dollars, and 500,000 shares of free trading shares valued at sixty five thousand dollars from a third party (QU CUI You) for 30 days advertising. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).

READ MORE AT: 
Authored by, pennylynnomega
Log in or register to post Private Message
Advertise with us

Add new comment

By submitting this form, you accept the Mollom privacy policy.